Clinical trial

Kinetics of Methemoglobin Concentration in Healthy Subjects Exposed to High Dose Inhaled Nitric Oxide

Name
2022P002884
Description
The goal of this clinical trial is to learn about the kinetic of methemoglobin in healthy subjects breathing high dose inhaled nitric oxide. The main questions it aims to answer are: * What are the kinetics of methemoglobin formation at a maximum of 300 parts per million of nitric oxide and oxygen * What are the kinetics of methemoglobin reduction after nitric oxide discontinuation Participants will be exposed to intermittent high dose inhaled nitric oxide at a maximum of 300 parts per million while being continuously monitored.
Trial arms
Trial start
2023-10-16
Estimated PCD
2025-06-01
Trial end
2025-12-01
Status
Recruiting
Phase
Early phase I
Treatment
Inhaled Nitric Oxide
Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
Arms:
Nitric Oxide
Other names:
Nitric Oxide, Gaseous Nitric Oxide
Size
10
Primary endpoint
Methemoglobin kinetics
7 days
Eligibility criteria
Inclusion Criteria: * 18 - 64 years-old volunteers. * Body Mass Index (BMI) 18 - 30 kg/m2. * Absence of current systemic and/or respiratory diseases. * Capacity to consent to the study. Exclusion Criteria: * Evidence of any physical, mental, and/or medical conditions that would make the proposed studies relatively more hazardous. * Systemic and/or respiratory disease with or without any functional limitation. * Left ventricle ejection fraction \< 30%. * Baseline MetHb ≥ 3% * Other conditions of increased risk for MetHb formation: genetic diseases (e.g., glucose-6-phosphate dehydrogenase deficiency, cytochrome b5 reductase deficiency, sickle cell disease), significant anemia or baseline elevation in MetHb. * History of transient ischemic attack or stroke. * Active smoking and tobacco chewers. Volunteers may be enrolled if they quit smoking for more than 1 year and less than 10 pack years total. * Any vaping/e-cigarettes use * Excess alcohol use: more than ½ L/day of wine consumption or equivalent * Current use of any recreational drugs (including the use of medical marijuana) or use of recreational drugs over the past year. * Pregnancy determined by blood pregnancy test detecting presence of human chorionic gonadotropin (hCG). * Less than six weeks postpartum. * Any current medication uses except oral contraceptives. * Lower respiratory infection within the last 30 days. * Claustrophobia (inability to wear a facemask) or other active psychiatric conditions or unwillingness to cooperate with the investigators and other medical teams. * Currently enrolled in another research study. * Facial abnormalities that would preclude proper use of a face mask.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Physiologic study in healthy volunteers', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}
Updated at
2023-10-18

1 organization

1 product

1 indication